FinanceAdmin•Yahoo Finance RSS•7 hours ago

Truist Adjusts Price Target for Alnylam Pharmaceuticals to $505

Truist has lowered its price target for Alnylam Pharmaceuticals from $515 to $505, indicating a shift in market outlook.

• Truist has revised its price target for Alnylam Pharmaceuticals, lowering it from $515 to $505.
• This adjustment reflects changes in market conditions and the company's performance outlook.
• Investors should consider this new target when evaluating their positions in Alnylam Pharmaceuticals.

Source: Yahoo Finance RSS

Northcoast Issues $5 Sell Rating on Hertz: Is the Rally Coming to an End?

Declining Retirement Confidence Among Middle-Class Americans Over 50

Bank Executives Concerned About AI-Driven Cyber Threats

Related Articles